RxDoctor Payments Data

Elise McCormack-Granja, MD

Internal Medicine · Miami, FLNPI 1417190752

Payments from drug & device makers

$1,002in general payments, 2019–2025

Across 51 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$381
  • AstraZeneca$119
  • Pfizer$91
  • Exact Sciences$84
  • Sanofi-aventis U.S. LLC$48
  • Amarin Pharma, Inc.$46
  • plus $233 from 9 others

What the payments were for

  • Food & beverage$1,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,002 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,754
Medicare patients
125
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$83,633
JardianceEmpagliflozin57$62,716
EliquisApixaban37$38,569
ProliaDenosumab17$28,592
MounjaroTirzepatide20$21,388
Synjardy XrEmpagliflozin/Metformin Hcl19$19,146
RybelsusSemaglutide14$18,431
XareltoRivaroxaban17$16,313
VascepaIcosapent Ethyl27$15,827
TradjentaLinagliptin11$14,443
WegovySemaglutide11$13,958
DipentumOlsalazine Sodium13$13,160
Tresiba Flextouch U-100Insulin Degludec13$7,936
Janumet XrSitagliptin Phos/Metformin Hcl12$6,500
Breo ElliptaFluticasone/Vilanterol11$5,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$381$116,022104 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$19$96,30587 claims
PfizerEliquis$91$38,56937 claims
AmgenProlia$16$28,59217 claims
Lilly USA, LLCMounjaro$29$21,38820 claims
GSKBreo Ellipta$33$5,89011 claims
AbbVieSynthroid$43$3,32539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →